Survival outcomes for dose‐dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple‐negative breast cancer: A prospective cohort study with propensity‐matched analysis - Xiu - 2022 -
Nomogram Predicting Bladder Cancer–specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium - European Urology Focus
Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27 | Journal of Clinical Oncology
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer - ScienceDirect
Platinum-based Neoadjuvant Chemotherapy Improves Oncological Outcomes in Patients with Locally Advanced Upper Tract Urothelial Carcinoma - European Urology Focus
Short-term outcome of neoadjuvant immunotherapy and chemotherapy in non–small cell lung cancer: A systematic review and meta-analysis - ScienceDirect
Cancers | Free Full-Text | Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer
Comparing outcomes following total neoadjuvant therapy and following neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer - eClinicalMedicine
Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer in: Journal of the National Comprehensive Cancer Network Volume 15 Issue 10 (2017)
Locoregional Management After Neoadjuvant Chemotherapy | Journal of Clinical Oncology
Neutrophil–lymphocyte ratio reflects tumour‐infiltrating lymphocytes and tumour‐associated macrophages and independently predicts poor outcome in breast cancers with neoadjuvant chemotherapy - Li - Histopathology - Wiley Online Library
Cancers | Free Full-Text | Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients - The Lancet Oncology
Cancers | Free Full-Text | Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial
Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. | Semantic Scholar
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC | Nature Cancer
Impact of Total Neoadjuvant Therapy on Postoperative Outcome... : Diseases of the Colon & Rectum
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients - The Lancet Oncology
Efficacy Outcomes Post-Surgery with Neoadjuvant Chemotherapy Regimen | Download Scientific Diagram
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer | NEJM
The concept of neoadjuvant therapy in breast cancer - OWise UK
Long-term Results After Neoadjuvant Chemotherapy for Breast Cancer: A Single-center Experience | Anticancer Research
Non-invasive intravoxel incoherent motion MRI in prediction of histopathological response to neoadjuvant chemotherapy and survival outcome in osteosarcoma at the time of diagnosis | Journal of Translational Medicine | Full Text
Treatment outcome in patients with stage III breast cancer treated with neoadjuvant chemotherapy
Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: A network meta-analysis - eClinicalMedicine
Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR) | Breast Cancer Research | Full
